Related Experiment Video
Updated: Apr 20, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
1.1K
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human
M Ceccon1, L Mologni2, G Giudici3
1Department of Health Science, University of Milano-Bicocca, Monza, Italy. mceccon.manuscript@gmail.com.
Molecular Cancer Research : MCR
|November 26, 2014
Summary
This study investigates resistance mechanisms to AP26113, a tyrosine kinase inhibitor (TKI), in anaplastic large cell lymphoma (ALCL) models. Findings reveal NPM-ALK overexpression and specific ALK mutations as key drivers of AP26113 resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic large cell lymphoma (ALCL) often involves the NPM-ALK fusion protein.
- ALK tyrosine kinase inhibitors (TKIs) like Crizotinib are used for advanced ALK-positive cancers.
- Drug resistance, often due to ALK mutations, limits TKI efficacy.
Purpose of the Study:
- To establish and characterize models of resistance to the ALK/EGFR inhibitor AP26113 in ALCL.
- To elucidate the molecular mechanisms underlying AP26113 resistance.
Main Methods:
- Development of AP26113-resistant NPM-ALK-positive ALCL cell lines (KARPAS-299, SUP-M2).
- Assessment of drug sensitivity (IC50 values) in resistant cell lines.
- Identification of resistance mechanisms through NPM-ALK expression analysis and ALK kinase domain mutation screening.
Main Results:
- Resistant cell lines exhibited 130- to 1,000-fold higher IC50 values compared to parental lines.
- KARPAS-299 resistant cells showed NPM-ALK overexpression.
- SUP-M2 resistant cells harbored various ALK kinase domain mutations, including L1196M, S1206C, F1174V+L1198F, and L1122V+L1196M.
Conclusions:
- Established reliable ALCL models for studying AP26113 resistance.
- Identified NPM-ALK overexpression and specific ALK mutations as key resistance mechanisms.
- Provides insights for managing patients with relapsed or refractory ALK-targeted therapy.
